
==== Front
Discov Oncol
Discov Oncol
Discover Oncology
2730-6011
Springer US New York

39225917
1282
10.1007/s12672-024-01282-9
Research
Diagnostic value and clinical significance of serum miR-4534 combined with transvaginal color Doppler ultrasound in cervical cancer
Shao Xiyan 1
Bai Lu 2
Liang Jinlan 1
Li Ming Limingsz_dr@163.com

3
1 grid.10784.3a 0000 0004 1937 0482 Department of Ultrasound Medicine, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Shenzhen, 518172 Guangdong People’s Republic of China
2 https://ror.org/01me2d674 grid.469593.4 0000 0004 1777 204X Department of Ultrasound Medicine, Nanhai Maternity & Child Healthcare Hospital of Foshan, Guangdong, 528299 People’s Republic of China
3 grid.10784.3a 0000 0004 1937 0482 Health Management Center, The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, No.53, Aixin Road, Longcheng Street, Longgang District, Shenzhen, Guangdong 518172 People’s Republic of China
3 9 2024
3 9 2024
12 2024
15 40318 6 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Aim

The purpose of the present study was to evaluate the diagnostic performance of serum miR-4534 combined with Transvaginal Color Doppler Ultrasound (TVCDS) in cervical cancer patients.

Methods

Blood samples from 126 patients with cervical cancer and 83 patients with benign uterine lesions were retrospectively analyzed. Quantitative real time polymerase chain reaction (qRT-PCR) was applied to examine the relative abundances of serum miR-4534 in cervical cancer based on a case–control study. Chi-square test was adopted to analyze the association between serum miR-4534 and other clinicopathological factors. The blood flow of cervix was examined using TVCDS, and the blood flow resistance index (RI) of cervix was summarized. Receiver operating characteristic (ROC) curves were plotted to explore the diagnostic capacity of serum miR-4534 combined with blood flow RI. Logistic regression was employed to analyze the risk factors of cervical cancer.

Results

Serum miR-4534 was distinctly increased in the study group compared with the control group (P < 0.05), while blood flow RI was dramatically decreased (P < 0.05). Moreover, increased miR-4534 was closely associated with lymph node metastasis (P = 0.010), FIGO stage (P = 0.007) and HR-HPV (P = 0.025). ROC curves demonstrated that the area under curve (AUC) of serum miR-4534 combined with the blood flow RI was 0.854, with the sensitivity and specificity of 88.9% and 73.5%, respectively, which displayed a better diagnostic capacity than serum miR-4534 and blood flow RI alone. Logistic regression analysis demonstrated that serum miR-4534 (OR = 8.805, 95% CI = 4.124–18.798; P < 0.001) was a risk factor related to the initiation and formation of cervical cancer, as well as blood flow RI (OR = 0.112; 95% CI = 0.054–0.235; P < 0.001).

Conclusion

Serum miR-4534 was highly expressed in cervical cancer, and associated with the development and metastasis of cervical cancer patients. MiR-4534 combined with TVCDS exhibited a considerable biomarker to detect cervical cancer patients.

Keywords

MiR-4534
RI
Diagnosis
ROC
TVCDS
issue-copyright-statement© Springer Science+Business Media, LLC 2024
==== Body
pmcIntroduction

Cervical cancer is the one of the most frequent female malignancies worldwide, with high incidence rate and mortality [1]. Infection with high-risk human papillomavirus (HR-HPV) infection is considered as the number one risk factor for cervical cancer [2]. HR-HPV infection itself is not enough to cause malignant transformation, but also involves other genetic and epigenetic changes, such as smoking, parity, oral contraceptives, and so on [3]. While HPV detection has a high sensitivity rate, its specificity remains poor. This makes it prone to misdiagnosis. The gold standard remains pathological diagnosis, but its application is limited due to the invasive nature of the procedure [4]. Transvaginal color Doppler ultrasound (TVCDS) is a valuable tool for the determination of the location and size of uterine tumors, as well as the assessment of blood flow status. However, its diagnostic accuracy of the technique is subjective and professional, leading to poor sensitivity and specificity [5]. In order to ensure the more effective clinical application, it is essential to combine with other relevant indicators.

MicroRNAs (miRNAs) are typically 21–25 nucleotides in length. As noncoding RNAs, they act as non-coding RNAs that negatively modulate the expression of their target genes at the post-transcriptional level [6]. They have been observed to participate in a number of different developmental processes, including differentiation, inflammation, apoptosis, and cell cycle modulation [7–9]. It has been established that alterations in miRNA expression can contribute to the onset of multiple tumors, including cervical cancer [10]. These miRNAs can promote or inhibit tumors, leading to tumor formation and the development of cancer. These oncogenic miRNAs are not only therapeutic targets but also important biomarkers for the detection and management of cancer [11]. As a less-studied miRNA, miRNA-4534 represents a typical multifunctional miRNA, which is related to the development of tumors, such as prostate cancer [12], cervical cancer [13].

In the present study, we measured the relative abundance of serum miR-4534 in cervical cancer patients and patients with benign uterine lesions, and recorded the blood flow RI of all subjects via TVCDS. Moreover, this study also evaluated the diagnostic accuracy of serum miR-4534 combined with blood flow RI for distinguishing cervical cancer patients from benign uterine lesions individuals.

Materials and methods

Patients and serum samples

One hundred and twenty-six cervical cancer patients pathologically confirmed were selected as the study group from The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen. 83 patients with benign uterine lesions were selected as the control group in this case–control study. Whole blood samples were collected in serum separator tubes from cervical cancer patients and patients with benign uterine lesions before operation. The collected serum was placed at 4 ℃, and centrifuged to remove the residual blood cells. Then, all the serum samples were preserved in − 80 ℃ refrigerator for further analysis.

Criterial for inclusion: postoperative diagnosis confirmed by pathological diagnosis; preoperative TVCDS examination and complete examination data; control group in good mental state with no other acute and chronic infectious diseases. Criterial for extraction: combined with other malignant tumors or severe cardiovascular and cerebrovascular diseases; serious functional abnormalities of the liver, kidneys and other major organs; combined with blood-borne infectious diseases.

All participants have signed informed consents. The Ethics Committee of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen have reviewed and supported the application for serum samples.

HR-HPV examination

Blood DNA from the subjects was extracted using a whole genome kit, and amplified using the PCR kit. HR-HPV infection was examined using a hybridization kit and a medical nucleic acid molecular rapid hybridizer. Viral load was measured as the ratio of relative light units (RLU) to CutOff (CO), and an RLU/CO ratio ≥ 1.0 was regarded to be positive.

Quantitative real time polymerase chain reaction (QRT-PCR) assay

Total RNA from serum specimens was extracted using TRIzol Reagent (Invitrogen) in accordance with the direction provided by the manufacturer. Quantitative miRNA-4534 of serum samples were analyzed using qRT-PCR through the standard SYBR-Green PCR instructions (Applied Biosystems). RNU6B was employed to be an internal reference for normalization. The relative expression level of miR-4534 was determined using the equation of 2−△△CT, △CT = CTmiR-4534-CTinternal reference. Each rection was done in triplicate.

TVCDS examination

After admission, transverse, longitudinal and oblique multi-directional scanning was performed with a transvaginal probe at a frequency of 5–9 MHz using a color Doppler ultrasound machine (GE Voluson E8). Resistance index (RI) is recorded by pulse Doppler ultrasound, and the sampling line was parallel to the direction of blood flow as far as possible, and the clamping angel kept below 30 degrees, and the average value was calculated from three consecutive measurements.

Statistical analysis

All statistical analysis was carried out using SPSS 23.0 software (IBM, USA) and GraphPad Prism 9.0 (CA, USA). The continuous data was assessed using Student’s t test with the percentage (n, %). Chi-square test was applied to the assessment of categorical data between two groups. The relevance between serum miR-4534 expression and blood flow RI was assessed using Pearson’s correlation analysis. Receiver operating characteristic (ROC) curves were constructed to determine the area under the curve (AUC) to evaluate the diagnostic efficiency of serum miR-4534 and blood flow RI. Logistic regression analysis was adopted to analyze the risk factors affecting the occurrence of cervical cancer. P values were two-tailed and a P value less than 0.05 was recognized to be a statistical significance.

Results

Baseline information of all the subjects

Table 1 indicated basic data of cervical cancer patients and the control group. The average ages were 51.11 ± 3.04 and 50.83 ± 3.87 in cervical cancer patients and control group, respectively. The mean BMI (body mass index) was 22.55 ± 2.39 in cervical cancer patients, while 22.37 ± 2.07 in control group. 15 of 126 (11.90%) cervical patients have smoking history, while 13 of 83 (15.66%) in patients with benign uterine lesions. There were 37 patients with menopausal (29.37%) in 126 cervical cancer patients, while 21 cases (25.30%) with menopausal in 83 control individuals. 10 cases with incidence of other sexually transmitted diseases (STDs) (7.94%) existed in 126 cervical cancer patients, while 6 of 83 (7.23%) in patients with benign uterine lesions. There were no significant association in age, BMI, smoking history, menopausal and STDs (all P > 0.05) between the study group and the control group. The cervical cancer patients with HR-HPV were 31 cases (24.60%), while 9 cases (10.84%) with HR-HPV in patients with benign uterine lesions. There was a dramatic association between the incidence of HR-HPV in the study group and the control group (P = 0.013) (Table 1).Table 1 Baseline information of cervical cancer group and the control group

Factors	Cervical cancer (n = 126)	Control (n = 83)	P value	
Age (years)	51.11 ± 3.04	50.83 ± 3.87	0.580	
BMI (kg/m2)	22.55 ± 2.39	22.37 ± 2.07	0.560	
Smoking history (n, %)	15 (11.90%)	13 (15.66%)	0.435	
Menopausal (n, %)	37 (29.37%)	21 (25.30%)	0.521	
HR-HPV	31 (24.60%)	9 (10.84%)	0.013	
STDs	10 (7.94%)	6 (7.23%)	0.851	
BMI: Body Mass Index; HR-HPV: high risk Human Papilloma Virus; STDs: incidence of other sexually transmitted diseases

P < 0.05 means significant difference

Relative abundances of serum miR-4534 and the values of blood flow RI in subjects

To investigate the role of serum miR-4534 in cervical cancer, qRT-PCR assay was conducted. It was suggested that serum miR-4534 levels were distinctly elevated in cervical cancer patients in comparison to patients with benign uterine lesions (P < 0.05, Fig. 1A). According to TVCDS examination, relative to the control group, the blood flow RI of cervical cancer patients was distinctly reduced (P < 0.05, Fig. 1B).Fig. 1 Serum miR-4534 expression in cervical cancer patients and the control group. A: Serum miR-4534 expression was distinctly increased in cervical cancer patients compared with controls (P < 0.05); B: The blood flow RI was significantly diminished in cervical cancer patients compared with control group (P < 0.05); C: Serum miR-4534 was negatively correlated with blood flow RI value between two groups via Pearson’s correlation analysis (r = − 0.6073; P < 0.001)

To explore the relevance of serum miR-4534 and blood flow RI, Pearson correlation analysis was carried out. As indicated in Fig. 1C, there was a negative correlation between serum miR-4534 and blood flow RI (r = − 0.6073, P < 0.001).

Correlation between serum miR-4534 expression and clinicopathological variables

In order to assess the relevance of serum miR-4534 with clinical factors, Chi-square was conducted. Based on the median value of serum miR-4534 level, all cervical cancer patients were classified into two groups, such as low miR-4534 expression group and high miR-4534 expression group. As summarized in Table 2, increased miR-4534 expression was notable associated with lymph node metastasis (LNM) (P = 0.010), FIGO stage (P = 0.007) and HR-HPV (P = 0.025). Nevertheless, no obvious correlations were found between serum miR-4534 expression and other clinicopathological factors, such as age, tumor size and differentiation (all P > 0.05).Table 2 Associations of serum miR-4534 expression and clinicopathological parameters

Factors	NO. (n = 126)	MiR-4534 expression	χ2	P value	
Low expression (n = 58)	High expression (n = 68)	
Age (years)				0.090	0.764	
 < 50	32	14	18			
 ≥ 50	94	44	50			
Tumor size (cm)				0.753	0.385	
 < 4	73	36	37			
 ≥ 4	53	22	31			
Differentiation				1.759	0.185	
 Well-Moderate	68	35	33			
 Poor	58	23	35			
LYM				6.570	0.010	
 Negative	76	42	34			
 Positive	50	16	34			
FIGO stage				7.397	0.007	
 I–II	82	45	37			
 III–IV	44	13	31			
HR-HPV				5.000	0.025	
 No	95	49	45			
 Yes	31	9	22			
LYM: lymph node metastasis; FIGO: The Federation International of Gynecology and Obstetrics; HR-HPV: high risk human papillomavirus

P < 0.05 means significant difference

Analysis of risk factors related to cervical cancer

Moreover, the influence of clinical factors on cervical cancer was analyzed by logistic regression. Univariate logistic analysis indicated that HR-HPV (P = 0.016; OR = 2.683; 95% CI = 1.203–5.983), blood flow RI (P < 0.001; OR = 0.139; 95% CI 0.074–0.259) and miR-4534 (P < 0.001, OR = 6.970; 95% CI = 3.680–13.204) were tightly associated with the initiation and formation of cervical cancer. Additionally, multivariate logistic analysis suggested that serum miR-4534 (OR = 8.805, 95% CI = 4.124–18.798; P < 0.001) was an independent risk factor for cervical cancer, together with blood flow RI (OR = 0.112; 95% CI = 0.054–0.235; P < 0.001) (Table 3).Table 3 Logistic analysis of clinical features related to cervical cancer

Factor	Univariate analysis	Multivariate analysis	
OR (95% CI)	P	OR (95% CI)	P	
Age	1.025 (0.944–1.112)	0.559	–	–	
BMI	1.038 (0.917–1.174)	0.558	–	–	
Smoking	0.728 (0.327–1.621)	0.436	–	–	
Menopausal	1.227 (0.656–2.295)	0.521	–	–	
HR-HPV	2.683 (1.203–5.983)	0.016	2.313 (0.842–6.350)	0.104	
STDs	1.106 (0.386–3.169)	0.851	–	–	
RI	0.139 (0.074–0.259)	<0.001	0.112 (0.054–0.235)	<0.001	
MiR-4534	6.970 (3.680–13.204)	<0.001	8.805 (4.124–18.798)	<0.001	
BMI: Body Mass Index; HR-HPV: high risk Human Papilloma Virus; STDs: incidence of other sexually transmitted diseases; RI: resistance index; miR-4534: microRNA-4534; OR: odds ratio; CI: confidence interval

P < 0.05 means significant difference

Diagnostic performance of serum miR-4534 and blood flow RI

ROC curves were plotted to evaluate the diagnostic capacity of miR-4534 and blood flow RI in cervical cancer. The AUCs for distinguishing cervical cancer from benign uterine lesions were 0.811 for serum miR-4534 (Fig. 2A), and 0.787 for blood flow RI (Fig. 2B). The sensitivity and specificity of serum miR-4534 were 85.7% and 72.3%, respectively; while those of blood flow RI were 79.4% and 75.9%, respectively. Based on the cut-off value of 1.255 for serum miR-4534, 126 patients with cervical cancer contained 108 true positives and 18 false negatives, while 60 true negatives and 23 false positives in controls. The positive predictive rate was 82.44% (108/108 + 23), and the negative predictive rate was 76.92% (60/60 + 18). Then, in order to test whether combining the two could improve the diagnostic performance, a diagnostic model was constructed using logistic regression. ROC was draw following the prediction probability of the combined index determined by regression equation. It was demonstrated that the combination brought out in a superior capacity to distinguish between cervical cancer from patients and benign uterine lesions with an AUC of 0.854. Correspondingly, the sensitivity and specificity were 88.9% and 73.5%, respectively (Fig. 2C).Fig. 2 ROC curve of serum miR-4534, RI and the combination for diagnosing cervical cancer. A AUC value of serum miR-4534 was 0.811 with the sensitivity of 85.7% and specificity of 72.3% to discriminate the cervical cancer patients from controls. B The AUC value of RI value was 0.787 with the sensitivity of 79.4% and 75.9% to distinguish between cervical cancer patients and controls. C The sensitivity and specificity were 88.9% and 73.5%, respectively, when combining miR-4534 and RI, to detect the cervical cancer

Discussion

Cervical cancer is one of the most frequent female malignant tumors with a high morbidity and mortality rate in China [14, 15]. The early symptoms of the malignant tumor are atypical, and the current screening approaches have defects in sensitivity and specificity as well as operability, so it is easy to miss the best opportunity for diagnosis and treatment [16]. Non-invasive diagnostic serum biomarkers have been widely used for the early detection of numerous types tumors, such as AFP for hepatocellular carcinoma and PSA for prostate cancer [17, 18]. In the context of cervical cancer, certain serum indicators were also examined for the purpose of screening for tumors, including glycoantigen (CA125) and carcinoembryonic antigen (CEA) [19]. However, the exploration of serum biomarkers with considerable specificity and sensitivity has not yet been achieved. Thus, it is of great importance to identify potential indicator of cervical cancer at the early stage.

Relatively conservative endogenous RNAs, miRNAs are able to regulate post-transcriptional genes. Research have shown that a large number miRNA genes are located in tumor-associated gene regions and different RNAs play different roles in the cancer initiation, metastasis and invasion [20]. Abnormal miRNAs played a central role in the development and progression of tumor by targeting downstream genes [21]. MiRNAs are abundant and stable in peripheral blood and they are potential serological detectors of tumors [22, 23]. Due to their high metabolic rate, malignant tumor cells require a richer blood supply to meet their proliferative needs, leading to abnormal blood flow [24]. Doppler ultrasound blood flow parameters can evaluate the blood richness and blood flow status of tumor blood vessels, and it is a commonly used diagnostic tool in the clinic [25]. In this study, we explored the value of serum miR-4534 combined with blood flow RI in the diagnosis of cervical cancer. It could provide an efficient and non-invasive method for the screening and diagnosis of cervical cancer.

We discovered a high HR-HPV infection rate in cervical cancer patients compared with benign uterine lesions patients. Moreover, serum miR-4534 levels were notably up-regulated in cervical cancer patients in comparison to benign uterine lesions patients. Nip et al. reported that miR-4534 was increased both prostate cancer tissues and cells, and silencing miR-4534 could inhibit cell growth and induce cell apoptosis, which provided a potential target for treatment of prostate cancer [12]. Relevant research had shown that miR-4534 was up-regulated based on the microarray experiments, displaying promising prognosis for cervical cancer patients with positive LNM  at an early stage [13]. These findings are consistent with what we found, and suggest that miR-4534 was a tumor promoter in the development of cervical cancer.

On the other hand, blood flow RI values were distinctly reduced in the study group relative to the control group. Pearson’s correlation analysis showed that a negative correlation was exhibited between serum miR-4534 expression and blood flow RI value. In addition, increased expression of miR-4534 was closely related to LNM, FIGO stage and HR-HPV. Furthermore, multivariate logistic regression indicated that blood flow RI and serum miR-4534 were the risk factors to influence the initiation and formation of cervical cancer, indicating that the above factors reflect the risk of cervical cancer to some extent. Serum miR-4534 and blood flow RI yielded a greater degree of influence on the occurrence of cervical cancer, suggesting that these two indicators have the potential to diagnose cervical cancer patients. Therefore, based on clinical experience, the diagnostic performance of serum miR-4534 and blood flow RI was deeply studied in this study.

In this study, the ROC curve analysis showed that the AUC of miR-4534 for diagnosing cervical cancer was 0.811, and the sensitivity and specificity were 85.7% and 72.3%, which suggests that serum miR-4534 has a certain diagnostic performance for cervical cancer. The AUC of serum miR-4534 combined with blood flow RI in the diagnosis of cervical cancer was 0.854, and the sensitivity (88.9%) and specificity (73.5%) were better than those of single biomarker. Low blood flow RI and high levels of serum miR-4534 were the independent risk factors affecting cervical cancer. Published research claimed that serum miR-18a, miR-130a and miR-92a combined with TVCDS exhibited a considerable diagnostic capacity for the detection of cervical cancer [26].

To sum up, serum miR-4534 was up-regulated and blood flow RI was reduced in patients with cervical cancer. The detection of blood flow RI by TVCDS combined with serum miR-4534 exhibited a considerable diagnostic capacity, which is used to distinguish cervical cancer patients from patients with benign uterine lesions. The combination diagnostic approach exhibited easy operation, and could improve the diagnostic rate of CC at an early stage.

However, due to the sample size and working conditions of the research, the relationship between HR-HPV infection and blood flow RI and serum miR-4534, and its molecular mechanism remain unexplored, which require further investigation. This study still needs multi-center cooperation to carry out a large-scale epidemiological investigation and research, and at the same time cooperate with the basic laboratory to explore the theoretical basis of serological index changes.

Acknowledgements

None.

Author contribution

Xiyan Shao, Lu Bai, Jinlan Liang made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data, and draft of the manuscript. Ming Li revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Funding

No funding was received for conducting this study.

Data availability

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Code availability

Not applicable.

Declarations

Ethics approval and consent to participate

The protocol was approved by The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Xiyan Shao and Lu Bai contributed equally to this work.
==== Refs
References

1. Johnson CA James D Marzan A Armaos M Cervical cancer: an overview of pathophysiology and management Semin Oncol Nurs 2019 35 2 166 174 10.1016/j.soncn.2019.02.003 30878194
Johnson CA, James D, Marzan A, Armaos M. Cervical cancer: an overview of pathophysiology and management. Semin Oncol Nurs. 2019;35(2):166–74. 10.1016/j.soncn.2019.02.003.30878194 10.1016/j.soncn.2019.02.003
2. Zhou Y Investigation of the clinical application value of HR-HPV DNA combined with liquid based cytology in colposcopy of cervical cancer Contrast Media Mol Imaging 2022 2022 5054507 10.1155/2022/5054507 36105441
Zhou Y. Investigation of the clinical application value of HR-HPV DNA combined with liquid based cytology in colposcopy of cervical cancer. Contrast Media Mol Imaging. 2022;2022:5054507. 10.1155/2022/5054507.36105441 10.1155/2022/5054507
3. Fang J Zhang H Jin S Epigenetics and cervical cancer: from pathogenesis to therapy Tumour Biol 2014 35 6 5083 5093 10.1007/s13277-014-1737-z 24554414
Fang J, Zhang H, Jin S. Epigenetics and cervical cancer: from pathogenesis to therapy. Tumour Biol. 2014;35(6):5083–93. 10.1007/s13277-014-1737-z.24554414 10.1007/s13277-014-1737-z
4. Brandt B Levin G Leitao MM Jr Radical hysterectomy for cervical cancer: the right surgical approach Curr Treat Options Oncol 2022 23 1 1 14 10.1007/s11864-021-00919-z 35167007
Brandt B, Levin G, Leitao MM Jr. Radical hysterectomy for cervical cancer: the right surgical approach. Curr Treat Options Oncol. 2022;23(1):1–14. 10.1007/s11864-021-00919-z.35167007 10.1007/s11864-021-00919-z
5. Tian Y Luo H Diagnostic accuracy of transvaginal ultrasound examination for local staging of cervical cancer: a systematic review and meta-analysis Med Ultrason 2022 24 3 348 355 10.11152/mu-3246 34762728
Tian Y, Luo H. Diagnostic accuracy of transvaginal ultrasound examination for local staging of cervical cancer: a systematic review and meta-analysis. Med Ultrason. 2022;24(3):348–55. 10.11152/mu-3246.34762728 10.11152/mu-3246
6. Lu TX Rothenberg ME MicroRNA J Allergy Clin Immunol 2018 141 4 1202 1207 10.1016/j.jaci.2017.08.034 29074454
Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–7. 10.1016/j.jaci.2017.08.034.29074454 10.1016/j.jaci.2017.08.034
7. Lin Z He H Wang M Liang J MicroRNA-130a controls bone marrow mesenchymal stem cell differentiation towards the osteoblastic and adipogenic fate Cell Prolif 2019 52 6 e12688 10.1111/cpr.12688 31557368
Lin Z, He H, Wang M, Liang J. MicroRNA-130a controls bone marrow mesenchymal stem cell differentiation towards the osteoblastic and adipogenic fate. Cell Prolif. 2019;52(6): e12688. 10.1111/cpr.12688.31557368 10.1111/cpr.12688
8. Chen C Guo M Zhao X Zhao J Chen L He Z MicroRNA-7: A new intervention target for inflammation and related diseases Biomolecules 2023 10.3390/biom13081185 38275755
Chen C, Guo M, Zhao X, Zhao J, Chen L, He Z, et al. MicroRNA-7: A new intervention target for inflammation and related diseases. Biomolecules. 2023. 10.3390/biom13081185.38275755 10.3390/biom13081185
9. Chen F Hu SJ Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review J Biochem Mol Toxicol 2012 26 2 79 86 10.1002/jbt.20412 22162084
Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol. 2012;26(2):79–86. 10.1002/jbt.20412.22162084 10.1002/jbt.20412
10. Shen S Zhang S Liu P Wang J Du H Potential role of microRNAs in the treatment and diagnosis of cervical cancer Cancer Genet 2020 248–249 25 30 10.1016/j.cancergen.2020.09.003 32987255
Shen S, Zhang S, Liu P, Wang J, Du H. Potential role of microRNAs in the treatment and diagnosis of cervical cancer. Cancer Genet. 2020;248–249:25–30. 10.1016/j.cancergen.2020.09.003.32987255 10.1016/j.cancergen.2020.09.003
11. Chen W Song J Bian H Yang X Xie X Zhu Q The functions and targets of miR-212 as a potential biomarker of cancer diagnosis and therapy J Cell Mol Med 2020 24 4 2392 2401 10.1111/jcmm.14966 31930653
Chen W, Song J, Bian H, Yang X, Xie X, Zhu Q, et al. The functions and targets of miR-212 as a potential biomarker of cancer diagnosis and therapy. J Cell Mol Med. 2020;24(4):2392–401. 10.1111/jcmm.14966.31930653 10.1111/jcmm.14966
12. Nip H Dar AA Saini S Colden M Varahram S Chowdhary H Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer Oncotarget 2016 7 42 68371 68384 10.18632/oncotarget.12031 27634912
Nip H, Dar AA, Saini S, Colden M, Varahram S, Chowdhary H, et al. Oncogenic microRNA-4534 regulates PTEN pathway in prostate cancer. Oncotarget. 2016;7(42):68371–84. 10.18632/oncotarget.12031.27634912 10.18632/oncotarget.12031
13. Barquet-Munoz SA Pedroza-Torres A Perez-Plasencia C Montano S Gallardo-Alvarado L Perez-Montiel D microRNA profile associated with positive lymph node metastasis in early-stage cervical cancer Curr Oncol 2022 29 1 243 254 10.3390/curroncol29010023 35049697
Barquet-Munoz SA, Pedroza-Torres A, Perez-Plasencia C, Montano S, Gallardo-Alvarado L, Perez-Montiel D, et al. microRNA profile associated with positive lymph node metastasis in early-stage cervical cancer. Curr Oncol. 2022;29(1):243–54. 10.3390/curroncol29010023.35049697 10.3390/curroncol29010023
14. Guo M Xu J Du J Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis BMC Public Health 2021 21 1 1329 10.1186/s12889-021-11401-8 34229639
Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health. 2021;21(1):1329. 10.1186/s12889-021-11401-8.34229639 10.1186/s12889-021-11401-8
15. Arbyn M Weiderpass E Bruni L de Sanjose S Saraiya M Ferlay J Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis Lancet Glob Health 2020 8 2 e191 e203 10.1016/S2214-109X(19)30482-6 31812369
Arbyn M, Weiderpass E, Bruni L, de Sanjose S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8(2):e191–203. 10.1016/S2214-109X(19)30482-6.31812369 10.1016/S2214-109X(19)30482-6
16. Voelker RA Cervical cancer screening JAMA 2023 330 20 2030 10.1001/jama.2023.21987 37889510
Voelker RA. Cervical cancer screening. JAMA. 2023;330(20):2030. 10.1001/jama.2023.21987.37889510 10.1001/jama.2023.21987
17. Tian S Chen Y Zhang Y Xu X Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma J Clin Lab Anal 2023 37 1 e24823 10.1002/jcla.24823 36579611
Tian S, Chen Y, Zhang Y, Xu X. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma. J Clin Lab Anal. 2023;37(1): e24823. 10.1002/jcla.24823.36579611 10.1002/jcla.24823
18. Becerra MF Atluri VS Bhattu AS Punnen S Serum and urine biomarkers for detecting clinically significant prostate cancer Urol Oncol 2021 39 10 686 690 10.1016/j.urolonc.2020.02.018 32241692
Becerra MF, Atluri VS, Bhattu AS, Punnen S. Serum and urine biomarkers for detecting clinically significant prostate cancer. Urol Oncol. 2021;39(10):686–90. 10.1016/j.urolonc.2020.02.018.32241692 10.1016/j.urolonc.2020.02.018
19. Meng H Zhang Y Chen Y Diagnosis value of colposcope combined with serum squamous cell carcinoma antigen, carbohydrate antigen 125, and carcinoembryonic antigen for moderate to advanced cervical cancer patients treated with modified fuzheng peiyuan decoction Evid Based Complement Alternat Med 2021 2021 4355805 10.1155/2021/4355805 35003300
Meng H, Zhang Y, Chen Y. Diagnosis value of colposcope combined with serum squamous cell carcinoma antigen, carbohydrate antigen 125, and carcinoembryonic antigen for moderate to advanced cervical cancer patients treated with modified fuzheng peiyuan decoction. Evid Based Complement Alternat Med. 2021;2021:4355805. 10.1155/2021/4355805.35003300 10.1155/2021/4355805
20. Saliminejad K Khorram Khorshid HR Soleymani Fard S Ghaffari SH An overview of microRNAs: Biology, functions, therapeutics, and analysis methods J Cell Physiol 2019 234 5 5451 5465 10.1002/jcp.27486 30471116
Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, Ghaffari SH. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019;234(5):5451–65. 10.1002/jcp.27486.30471116 10.1002/jcp.27486
21. Dayakar A Shanmukha KD Kalangi SK Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy Mol Biol Rep 2022 49 7 6827 6846 10.1007/s11033-021-07040-2 35031927
Dayakar A, Shanmukha KD, Kalangi SK. Spectrum of microRNAs and their target genes in cancer: intervention in diagnosis and therapy. Mol Biol Rep. 2022;49(7):6827–46. 10.1007/s11033-021-07040-2.35031927 10.1007/s11033-021-07040-2
22. Hamdi K Blancato J Goerlitz D Islam M Neili B Abidi A Circulating cell-free miRNA expression and its association with clinicopathologic features in inflammatory and non-inflammatory breast cancer Asian Pac J Cancer Prev 2016 17 4 1801 1810 10.7314/apjcp.2016.17.4.1801 27221856
Hamdi K, Blancato J, Goerlitz D, Islam M, Neili B, Abidi A, et al. Circulating cell-free miRNA expression and its association with clinicopathologic features in inflammatory and non-inflammatory breast cancer. Asian Pac J Cancer Prev. 2016;17(4):1801–10. 10.7314/apjcp.2016.17.4.1801.27221856 10.7314/apjcp.2016.17.4.1801
23. Wen G Gu W Circular RNAs in peripheral blood mononuclear cells are more stable than linear RNAs upon sample processing delay J Cell Mol Med 2022 26 19 5021 5032 10.1111/jcmm.17525 36039821
Wen G, Gu W. Circular RNAs in peripheral blood mononuclear cells are more stable than linear RNAs upon sample processing delay. J Cell Mol Med. 2022;26(19):5021–32. 10.1111/jcmm.17525.36039821 10.1111/jcmm.17525
24. Harris B Saleem S Cook N Searle E Targeting hypoxia in solid and haematological malignancies J Exp Clin Cancer Res 2022 41 1 318 10.1186/s13046-022-02522-y 36320041
Harris B, Saleem S, Cook N, Searle E. Targeting hypoxia in solid and haematological malignancies. J Exp Clin Cancer Res. 2022;41(1):318. 10.1186/s13046-022-02522-y.36320041 10.1186/s13046-022-02522-y
25. Niu J Ma J Guan X Zhao X Li P Zhang M Correlation between doppler ultrasound blood flow parameters and angiogenesis and proliferation activity in breast cancer Med Sci Monit 2019 25 7035 7041 10.12659/MSM.914395 31535669
Niu J, Ma J, Guan X, Zhao X, Li P, Zhang M. Correlation between doppler ultrasound blood flow parameters and angiogenesis and proliferation activity in breast cancer. Med Sci Monit. 2019;25:7035–41. 10.12659/MSM.914395.31535669 10.12659/MSM.914395
26. Wang Y Yang J Wang Y Serum miRNA combined with transvaginal color Doppler ultrasound diagnosis clinical research on cervical cancer J Ultrasound Med 2024 43 4 791 798 10.1002/jum.16413 38269478
Wang Y, Yang J, Wang Y. Serum miRNA combined with transvaginal color Doppler ultrasound diagnosis clinical research on cervical cancer. J Ultrasound Med. 2024;43(4):791–8. 10.1002/jum.16413.38269478 10.1002/jum.16413
